Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fenebrutinib - Genentech

Next Previous
Drug Profile

Fenebrutinib - Genentech

Alternative Names: GDC-0853; RG-7845; RO-7010939

Latest Information Update: 09 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genentech
  • Developer Chugai Pharmaceutical; Genentech
  • Class Antineoplastics; Antirheumatics; Piperazines; Pyrazines; Pyridines; Skin disorder therapies; Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Multiple sclerosis
  • No development reported Autoimmune disorders
  • Discontinued Chronic lymphocytic leukaemia; Chronic urticaria; Non-Hodgkin's lymphoma; Rheumatoid arthritis; Systemic lupus erythematosus

Most Recent Events

  • 02 Mar 2026 Efficacy and safety data from a phase III FENhance trial in Multiple sclerosis released by Genentech
  • 07 Feb 2026 Roche announces intention to file regulatory filing for Multiple sclerosis in mid first half of 2026 (Roche pipeline, August 2023)
  • 07 Feb 2026 Efficacy and adverse events data from a phase III FENtrepid trial in Multiple sclerosis released by Genentech

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top